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Introduction
Owing to their small size, nanoparticles have unique properties
compared with the bulk form of the same material. Despite
the speed of development of nanoparticles, relatively little is
known about their interactions with living systems. To further
understand the nature of nanoparticle interactions with biolog-
ical systems, nanoparticles must be engineered with reporters
that can be used to comprehend these interactions. Unfortu-
nately, engineering nanoparticles with reporters can be chal-
lenging.
The most common strategy used to monitor nanoparticles is
to conjugate reporters to the nanoparticle scaffold during syn-
thesis. The reporter can then be used to monitor the nanopar-
ticle in biological systems. Although this strategy is useful, it
has drawbacks that limit its utility. First, conjugating reporters
to nanoparticles complicates the synthesis because of the ad-
ditional steps and purifications. Second, many reporters them-
selves have distinct chemical characteristics that, if conjugated
to the nanoparticle, can alter the properties of the conjugate.[1]
Clearly, improved nanoparticle monitoring strategies are
needed to better understand how nanoparticles interact with
biological systems. In particular, the development of strategies
that are simple, rapid, and sensitive and do not require compli-
cated syntheses or alter the properties of the nanoparticle re-
mains highly desirable.
Recently, bioorthogonal reactions have emerged as promis-
ing tools for chemistry and biological applications. The [3+2]
cycloaddition between azides and terminal alkynes is one of
the first bioorthogonal reactions and was described by Huis-
gen more than four decades ago.[2] Although this reaction is
thermodynamically favorable, it requires harsh reaction condi-
tions that limit its use. To overcome some of these obstacles,
Sharpless and colleagues used a copper catalyst to accelerate
the reaction. This modification greatly expanded the utility of
this reaction and has led to more extensive applications in or-
ganic and polymer chemistry.[3] Additionally, because of the ef-
ficiency, selectivity, and mild reaction conditions, this class of
reactions is well suited for profiling endogenous macromole-
cules in biological systems. For example, the copper-catalyzed
azide–alkyne cycloaddition (CuAAC) has been used for in situ
conjugation of chemical reporters to monitor DNA synthesis,
metabolite flux, and protein trafficking.[4]
These studies demonstrated that the CuAAC reaction can be
used to monitor biomolecules and overcomes many of the lim-
itations of traditional reporter strategies. Synthetic nanoparti-
cles are similar in many respects to biomolecules, so we hy-
pothesized that the CuAAC reaction could be used to conju-
gate reporters to nanoparticles after their delivery to biological
systems. To explore this possibility, we synthesized dendrimer
scaffolds with alkyne chemical handles that could be used for
downstream CuAAC functionalization. This approach not only
allowed us to engineer multifunctional dendrimer conjugates,
but also provided a chemical handle that could be reacted
with azide-modified fluorescent reporters in biological systems.
We evaluated this reporter strategy in several biological sys-
Nanoparticle technologies have tremendous potential in clini-
cal medicine. To fully realize this potential, one must further
understand how nanoparticles interact with biological systems.
Typically, reporters that are conjugated to nanoparticles during
synthesis are used to monitor the nanoparticles in biological
systems. Unfortunately, conjugating reporters to nanoparticles
complicates the synthesis and the reporter itself may alter the
nanoparticle properties. To address these challenges, a copper-
catalyzed azide–alkyne cycloaddition strategy has been devel-
oped to functionalize nanoparticles with fluorescent reporters
after they have been delivered to biological systems. Using
polyamidoamine dendrimers as model nanoparticles, the utility
of this strategy is shown in several biological systems including
a cancer cell model, primary immune cells, and a murine
model of inflammation. This reporter strategy simplifies the
synthesis without sacrificing the ability to monitor the nano-
particle conjugates. It is expected that this bioorthogonal re-
porter strategy can be used to understand nanoparticle inter-
actions in biological systems, which will facilitate the transla-
tion of these technologies to the clinics.
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tems, including cancer and
immune cell models and an
animal model of inflammation.
We anticipate that this approach
will simplify the design of multi-
functional nanoparticles and can
be used to further understand
the biological behavior of nano-
particles, which will speed their




Figure 1 summarizes the strat-
egy to functionalize dendrimers
with chemical reporters in bio-
logical systems. To evaluate this
strategy, we first synthesized
G5-Alkyne 2 with 12.3 alkyne
handles per dendrimer (Fig-
ure S1 in the Supporting Infor-
mation). After synthesizing G5-
Alkyne 2, the other dendrimer
conjugates were functionalized
with azide-derivatized triazine
rings by using the CuAAC reaction (Scheme 1). For the reporter
strategy to be useful, it is important that the CuAAC reaction
efficiencies of the different dendrimer conjugates are similar so
that the conjugated reporter reflects the amount of dendrimer
present rather than differences in reaction efficiencies. To con-
firm that the reaction efficiencies were similar between dendri-
Figure 1. Schematic of the bioorthogonal reporter strategy for monitoring dendrimer conjugates. Dendrimers are engineered with surface alkyne handles
that can be further functionalized. The dendrimer conjugates are then delivered to biological targets. The dendrimer alkyne handles are reacted in situ with
azido-fluorescent reporters through the CuAAC reaction.
Scheme 1. G5-FA-Alkyne 1, G5-Alkyne 2, G5-Mannose-Alkyne 3, G5-FA-MTX-Alkyne 4, and G5-MTX-Alkyne 5.
G5=generation 5 polyamidoamine (PAMAM) dendrimer, FA= folic acid, MTX=methotrexate, Boc= tert-butoxycar-
bonyl.
 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemPlusChem 2013, 78, 430 – 437 431
CHEMPLUSCHEM
FULL PAPERS www.chempluschem.org
mer conjugates, we used
a “click” fluorescence assay that
consists of the ligation of
a quenched 3-azido-7-hydroxy-
coumarin reporter to alkyne-
functionalized dendrimer conju-
gates to form a triazole-linked
adduct. After the ligation, there
is an increase in fluorescence in-
tensity that reflects the CuAAC
reaction efficiency.[5] To evaluate
the CuAAC reaction efficiencies,
we reacted equal amounts of
the 3-azido-7-hydroxycoumarin
reporter with the different
alkyne-functionalized dendrimer
conjugates and assessed the re-
sulting fluorescence signal. After
1 hour, no significant differences
in fluorescence intensities be-
tween the different dendrimer
conjugates were found
(Table S1). These results confirm
that the CuAAC reaction effi-
ciencies are similar for the differ-
ent dendrimer conjugates.
In vitro evaluation of CuAAC
reporter strategy
We then evaluated the CuAAC
reporter strategy in a cancer cell
model. We and others have
shown that FA-functionalized
dendrimers internalize through
the folate receptor (FR) in the
KB cell line.[6] To evaluate the re-
porter strategy, we incubated G5-FA-Alkyne 1 and the nontar-
geted control G5-Alkyne 2 with KB cells for 1 hour at 37 8C.
After incubation, the cells were processed and AF647 dye (see
the Experimental Section) was conjugated to the internalized
dendrimer conjugates by using the CuAAC reaction. Similar to
traditional, fluorophore-labeled FA–dendrimer conjugates, the
G5-FA-Alkyne 1 demonstrated dose- and time-dependent
uptake into KB cells (Figure 2 and Figure S3). The uptake of G5-
FA-Alkyne 1 could be blocked by treatment with FA (100 mm),
thus confirming the FR specificity of the FA-targeted dendrimer
conjugates (Figure 2). The cells treated with the nontargeted
G5-Alkyne 2 showed no evidence of uptake, with fluorescence
signals similar to those of the untreated cells (Figure 2). Impor-
tantly, in the absence of the copper catalyst, there was no evi-
dence of increased fluorescence signal relative to controls,
which suggested strongly that the fluorescence signal is from
ligation of the fluorescent reporters with the internalized den-
drimer conjugates (Figure S4).
Evaluation of CuAAC reporter strategy with microscopy
After showing the utility of the reporter strategy with flow cy-
tometry, we explored its utility in microscopy applications. Al-
though flow cytometry provides valuable information, it does
not capture spatial information and relationships. Unfortunate-
ly, the use of fluorescent reporters can be more challenging in
microscopy applications because of the complex processing
protocols and the incompatibility of some fluorescent report-
ers.[7] Using a protocol that preserves cell monolayers, we eval-
uated the ability of the CuAAC reporter strategy to functional-
ize cell-internalized dendrimer conjugates that could be ana-
lyzed by confocal microscopy. KB cells were incubated with
either G5-FA-Alkyne 1 or the nontargeted control G5-Alkyne 2
for 1 hour at 37 8C. After the treatment, the cells were pro-
cessed and the internalized dendrimer conjugates were react-
ed with either AF488 or AF555 reporters by using the CuAAC
reaction. In agreement with the flow cytometry results, the in-
ternalized G5-FA-Alkyne 1 conjugates could be reacted with
azide-modified fluorescent reporters through the CuAAC reac-
Figure 2. In vitro demonstration of bioorthogonal reporter in a cancer cell model. A) KB cells were incubated with
G5-FA-Alkyne 1 and G5-Alkyne 2 for 1 h. The cells were harvested and the internalized dendrimers were reacted
with AF647 by using the CuAAC reaction and analyzed by flow cytometry. B) G5-FA-Alkyne 1 uptake was inhibited
by incubating with 100 mm folic acid (FA) for 30 min prior to treatment with the dendrimer conjugates. Cells were
analyzed by flow cytometry. C) KB cells were incubated with 30 nm G5-FA-Alkyne 1 and stained with 4’,6-diamidi-
no-2-phenylindole (DAPI ; blue), and internalized dendrimer conjugates were reacted with AF488 (green).
D) KB cells were incubated with the same G5-FA-Alkyne 1 conjugate as in (C). The cells were then stained with
DAPI (blue) and reacted with AF555 (red). Scale bars: 20 mm. Results are representative of three independent ex-
periments. MFI=median fluorescence intensity. No Tx=no treatment.
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tion and visualized by confocal microscopy (Figure 2). Addi-
tionally, we demonstrate the flexibility of this strategy by using
different fluorescent reporters without having to synthesize
new dendrimer conjugates.
Validation of CuAAC reporter strategy in a primary cell
model
To evaluate the generalizability of the CuAAC reporter strategy,
we engineered a-d-mannose dendrimer conjugates (G5-Man-
nose-Alkyne 3) that target tumor-associated macrophages
(TAMs) through the macrophage mannose receptor (MMR). a-
d-Mannose is a high-affinity ligand for the MMR, a type 1
membrane receptor that is present on TAMs and is being in-
vestigated for immune therapeutics.[8] The MMR is induced in
cytokine-polarized bone-marrow-derived macrophages
(BMDMs), thereby providing another receptor–ligand system to
test the in situ CuAAC reporter strategy.[9] The TAMs were incu-
bated with G5-Mannose-Alkyne 3 and the nontargeted G5-
Alkyne 2 for 6 h at 37 8C. The TAMs were then processed and
the internalized dendrimer conjugates were reacted with
AF647 by using the CuAAC reaction and then analyzed by flow
cytometry. The TAMs treated with G5-Mannose-Alkyne 3
showed an increase in fluorescence signal compared with
TAMs treated with G5-Alkyne 2 and nonpolarized BMDMs, thus
confirming the receptor-specific internalization of G5-Mannose-
Alkyne 3 (Figure 3). The cell-specific uptake and detection of
mannose-functionalized alkyne dendrimers by using the
CuAAC reporter strategy confirms the efficacy of this approach
for a broad spectrum of receptor–ligand systems, nanoparti-
cles, and cell types.
Evaluation of CuAAC reporter strategy to monitor multifunc-
tional dendrimer therapeutics
One important application for the in situ CuAAC reporter strat-
egy is to monitor multifunctional nanoparticles without having
to synthesize distinct, reporter-labeled conjugates. Typically,
nanoparticle therapeutics must be engineered with reporters
during their fabrication to allow monitoring in biological sys-
tems. Engineering of nanoparticles with these reporters com-
plicates their synthesis and the conjugated reporter itself may
alter the properties of the nanoparticle. To evaluate the utility
of the CuAAC reporter strategy to monitor nanoparticle thera-
peutics, we compared the binding properties of two closely re-
lated dendrimer therapeutics (G5-FA-MTX-Alkyne 4 and G5-
MTX-Alkyne 5) in a cancer cell model. We and others have
shown that decorating the surface of nanoparticles with tar-
geting ligands enhances the binding avidity compared with
the monovalent targeting ligand.[10] Although both FA and
MTX bind the FR, MTX has a 100-fold lower affinity than FA.[11]
Several studies using analytical techniques have demonstrated
that conjugating multiple MTX molecules to the dendrimer
surface enhances the binding affinity through multivalent re-
ceptor interactions.[12] However, these findings have not been
evaluated systematically in biological systems because of the
difficulties in engineering reporter-labeled nanoparticle thera-
peutics. Using the CuAAC reporter strategy to monitor the
dendrimer conjugates, we explored the binding properties of
dendrimer therapeutics in a culture model. We used the alkyne
handles to further functionalize the dendrimer conjugates
during the synthesis and also to attach the fluorescent report-
ers in biological systems, so the syntheses were greatly simpli-
fied without losing the ability to monitor the dendrimer conju-
gates. KB cells were treated with G5-FA-MTX-Alkyne 4 and G5-
MTX-Alkyne 5 for 1, 4, and 24 h. After the incubation, the cells
were processed and the internalized dendrimer conjugates
were reacted with azide reporters and analyzed by flow cytom-
etry as described above. The G5-FA-MTX-Alkyne 4 and G5-
MTX-Alkyne 5 both showed FR-specific uptake in the KB cells.
Interestingly, 4 was internalized more efficiently than 5 at all of
the time points examined (Figure 4). These findings build upon
our prior studies and suggest that the rate and total amount
of the G5-MTX-Alkyne 5 internalized are much less than G5-FA-
MTX-Alkyne 4. These types of biological studies on nanoparti-
cle properties are difficult to perform because of the compli-
cated synthetic schemes needed to engineer comparable re-
porter-labeled conjugates and the necessary controls. The
modularity of our synthetic approach and the strengths of the
CuAAC reporter strategy address some of these difficulties and
enable more extensive evaluations of the interactions between
nanoparticles and biological systems.
Figure 3. In vitro evaluation of bioorthogonal reporter in primary immune
cells. A) MMR was induced in BMDMs stimulated with interleukin 4 (IL-4) and
IL-10 as assessed by real-time quantitative reverse-transcription polymerase
chain reaction (qRT-PCR). B) IL-4- and IL-10-stimulated BMDMs were incubat-
ed with 30 nm G5-Mannose-Alkyne 3 and G5-Alkyne 2 for 6 h. BMDMs were
harvested and internalized dendrimer conjugates were reacted with AF647
and analyzed by flow cytometry. G5-Mannose-Alkyne 3 internalizes into
BMDMs stimulated with IL-4 and IL-10 but not into unstimulated BMDMs.
Results are representative of two independent experiments. No Tx=no
treatment.
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Validation of CuAAC reporter strategy in an animal model
of inflammation
After confirming the efficacy of our CuAAC reporter strategy in
vitro, we evaluated its utility to monitor nanoparticles in vivo.
One of the major obstacles slowing the translation of nanoma-
terials to the clinics is a limited
understanding of their biologi-
cal properties in vivo.[13] To eval-
uate the CuAAC reporter strat-
egy in vivo, we used a murine
model of inflammation and ex-
amined the uptake and traffick-
ing of G5-FA-Alkyne 1. We and
others have shown that thiogly-
collate administered intraperito-
neally (IP) induces recruitment
of folate receptor beta (FRb+)
inflammatory macrophages that
can bind and internalize FA-tar-
geted dendrimers.[14] On day 1,
mice (n=2) were treated with
thioglycollate to induce perito-
neal inflammation and recruit-
ment of FRb+ macrophages. On
day 3, mice were administered
35 mgkg1 G5-FA-Alkyne 1, G5-
Alkyne 2, or a vehicle control IP.
On day 4, peritoneal macro-
phages, submandibular lymph
nodes, and mesenteric lymph
nodes were isolated and pro-
cessed for single-cell suspen-
sions. The cell suspensions and
the internalized dendrimers
were reacted with azide-modi-
fied fluorescent reporters by
using the CuAAC reaction and analyzed by flow cytometry as
described above. As expected, the G5-FA-Alkyne 1 conjugates
were found in the FRb+ peritoneal macrophages and the FRb+
macrophages in the secondary lymph organs draining the peri-
toneal cavity (mesenteric lymph nodes; Figure 5). In contrast,
secondary lymph organs that do not drain the peritoneal
Figure 4. Monitoring dendrimer therapeutics by using the bioorthogonal reporter strategy. A) KB cells were incubated with 30 nm G5-FA-MTX-Alkyne 4 and
G5-MTX-Alkyne 5 for the indicated times. Cells were harvested at various time points and the internalized dendrimer therapeutics were reacted with AF647
by using the CuAAC. B) G5-FA-MTX-Alkyne 4 internalizes more rapidly and in a greater amount than G5-MTX-Alkyne 5. Results are representative of three in-
dependent experiments. No Tx=no treatment.
Figure 5. In vivo monitoring of dendrimer conjugates with the bioorthogonal reporter strategy. Mice were stimu-
lated with thioglycollate IP. Three days after stimulation, mice were treated IP with G5-FA-Alkyne 1 (200 mL,
35 mgkg1). On day 4, peritoneal macrophages, spleen, cervical lymph nodes, and mesenteric lymph nodes were
isolated and internalized dendrimers were reacted with AF647 and analyzed by flow cytometry. Results show
more G5-FA-Alkyne 1 uptake into macrophages from the mesenteric lymph node than the submandibular lymph
node, consistent with the immune trafficking of FRb+ peritoneal macrophages.
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cavity (submandibular lymph nodes) showed no evidence of
macrophages that had internalized the G5-FA-Alkyne 1, consis-
tent with the known trafficking patterns of the peritoneal mac-
rophages. Additionally, the peritoneal macrophages from
stimulated mice had a much higher uptake of G5-FA-Alkyne 1
than the control mice, consistent with the high prevalence of
FRb+ macrophages following activation with thioglycollate
(data not shown). These results show that the CuAAC reporter
strategy can be used to monitor nanoparticle trafficking in
animal models.
Conclusion
In summary, we have developed a bioorthogonal, copper-cata-
lyzed azide–alkyne cycloaddition reporter strategy to conju-
gate fluorescent reporters to nanoparticles in biological sys-
tems. To our knowledge, this is the first description of in situ
conjugation of reporters to synthetic nanoparticles to track
nanoparticles in vitro and in vivo. The nanoparticle alkyne han-
dles can be further functionalized after delivery to biological
systems, so there is no need to synthesize distinct reporter-la-
beled conjugates to monitor their trafficking. We believe that
this strategy provides an alternative to traditional labeling ap-
proaches while providing the flexibility for multiple reporters
as well as more detailed biological evaluations of multifunc-
tional nanoparticles. We envision that this bioorthogonal re-
porter strategy will be applicable to a broad spectrum of nano-
materials and opens the door for mechanistic studies on nano-




All solvents and chemicals were reagent-grade quality and were
purchased from Sigma–Aldrich. Generation 5 (G5) polyamidoamine
(PAMAM) dendrimer was purchased from Dendritech, Inc. , Midland,
Michigan. Alexa Fluor 488 azide (AF488), Alexa Fluor 555 azide
(AF555), Alexa Fluor 647 azide (AF647), trypsin-EDTA, and phos-
phate-buffered saline (PBS) were purchased from Life Technologies
(Carlsbad, CA, USA). All materials were used without further purifi-
cation unless otherwise noted.
General methods
All 1H NMR spectra were measured on a 500 MHz Varian NMR
system equipped with a multinuclear 5 mm probe. Mass spectra
were obtained on a Waters 1525 mass spectrometer. Silica gel 60
had particle size 0.040–0.063 mm and 230–400 mesh; thin-layer
chromatography was performed using Whatman adsorption plates,
60  silica gel, 250 mm layer thickness. Deionized water (18.2 MW)
was made with a Nanopure Infinity DI water system.
Characterization of dendrimer conjugates
The dendrimer conjugates and their structures are shown in
Scheme 1. The number of ligands attached to the dendrimer was
derived from the integration of the methyl protons of the terminal
acetyl groups to the aromatic protons from the conjugated ligands
(e.g. , FA and MTX) as described previously.[15] The number of acetyl
groups per dendrimer was determined by computing the total
number of end groups from the gel permeation chromatography
average molecular weight and potentiometric titration data for G5-
NH2 (100%) as described previously.
[15,16] The total number of end
groups was applied to the ratio of primary amines to acetyl
groups, obtained from the 1H NMR data of the partially acetylated
dendrimer, to compute the average number of acetyl groups per
dendrimer.
Ultraperformance liquid chromatography (UPLC) analysis was per-
formed on a Waters Acquity Peptide Mapping System equipped
with a Waters photodiode array detector, a column manager, and
a sample manager. The instrument was controlled by Empower 3
software. For characterization, calibration, and quantitation studies,
dendrimers were separated on an Acquity BEH C18 column (100
2.1 mm, 1.7 mm). The analysis was performed by using gradient
elution beginning with 99:1 (v/v) water/acetonitrile (MeCN) and
reaching 20:80 water/MeCN in 13.4 min. Trifluoroacetic acid
(0.14 wt% concentration) was added to the water as well as MeCN
as a counter ion. The gradient was then equilibrated back to the
starting conditions in the next 1.0 min. The flow rate was main-
tained at 0.208 mLmin1, the column temperature at 35 8C, and
the concentration of dendrimer at 1.0 mgmL1.
Synthesis of dendrimer conjugates
All conjugates and intermediates were purified by ultrafiltration
using 10000 molecular weight cutoff centrifugal filtration devices
(Millipore). Purification consisted of ten cycles (20 min at 4800 rpm)
using PBS (five cycles) and deionized water (five cycles). All conju-
gates and intermediates were characterized by MALDI-TOF, UPLC,
and 1H NMR spectroscopy.
Synthesis of FA and MTX dendrimer conjugates : G5-FA-Alkyne 1,
G5-Alkyne 2, G5-FA-MTX-Alkyne 4, and G5-MTX-Alkyne 5 were syn-
thesized as described previously.[17,18] G5-FA-Alkyne 1 (yellow solid):
1H NMR integration determined the mean number of FA units at-
tached to be 4.2; MALDI-TOF mass 33059. G5-Alkyne 2 (white
solid): By 1H NMR integration, the mean number of acetyl groups
per dendrimer was 80.1; the mean number of alkyne ligands per
dendrimer was 12.3; MALDI-TOF mass 32774. G5-FA-MTX-Alkyne 4
(yellow solid): 1H NMR integration determined the mean number of
triazine-MTX-FA units attached to be 3.1; MALDI-TOF mass 35094.
G5-MTX-Alkyne 5 (yellow solid): 1H NMR integration determined
the mean number of MTX units attached to be 3.7; MALDI-TOF
mass 34266.
Synthesis of G5-Mannose-Alkyne 3 : a-d-Mannopyranosylphenyl
isothiocyanate (1.5 mg, 4.8 mmol) in dimethyl sulfoxide (DMSO;
100 mL) was added to a solution of G5-Alkyne 2 (10.5 mg,
0.32 mmol) and N,N-diisopropylethylamine (1.2 mg, 9.3 mmol) in
DMSO (300 mL), and the reaction mixture was stirred at room tem-
perature for 24 h (see the Supporting Information, Scheme S1). The
purified product was lyophilized to yield 3 as a white solid
(11.4 mg, 95%). 1H NMR integration determined the mean number
of a-d-mannose moieties attached to be 11.5; MALDI-TOF
mass 36438.
Cell culture, treatments, and procedures
The KB cell line was purchased from the American Type Tissue Col-
lection (ATCC, Manassas, VA, USA) and cultured at 37 8C and 5%
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CO2 in RPMI 1640 medium (Mediatech, Herndon, VA, USA). The
RPMI 1640 medium was supplemented with penicillin
(100 unitsmL1), streptomycin (100 mgmL1), and 10% heat-inacti-
vated, low-endotoxin fetal bovine serum (FBS; Mediatech, Hern-
don, VA, USA). To induce high folate receptor a (FR) expression, the
KB cells were cultured in FA-depleted RPMI 1640 media for at least
4 days. Animals were handled in accordance with Animal Use Pro-
tocol 10260-1. Bone-marrow-derived macrophages (BMDMs) were
obtained as described previously.[19] Briefly, bone marrow precur-
sors from female C57BL/6 mice were isolated and matured for
7 days in RPMI 1640 media supplemented with penicillin
(100 unitsmL1), streptomycin (100 mgmL1), and 10% heat-inacti-
vated low-endotoxin FBS with L-cell conditioned media as a source
of macrophage colony-stimulating factor (M-CSF). Following their
maturation, BMDMs were polarized with murine recombinant M-
CSF (10 ngmL1), IL-4 (50 ngmL1), and IL-10 (10 ngmL1) for 72 h
(Peprotech, Rocky Hill, NJ, USA) to induce the macrophage man-
nose receptor (MMR). For flow cytometry assessments, cells were
seeded in 12-well dishes at a density of 100000 cells per well and
cultured for another 24 h prior to dendrimer treatments. The cells
were then incubated with the dendrimer conjugates at 37 8C for
the indicated times. The cells were washed and trypsinized or
scraped followed by centrifugation at 1500 rpm for 5 min to
obtain cell pellets. The pellets were washed twice with PBS and
then resuspended in PBS with 0.1% bovine serum albumin (BSA)
prior to flow cytometry assessment with an Accuri C6 flow cytome-
ter (Ann Arbor, MI, USA). Flow cytometry data were analyzed by
using FlowJo 8.2 software (TreeStar, New Brunswick, NJ, USA).
In situ CuAAC reaction with dendrimer conjugates
Cells were washed and pelleted as described above. The cell pel-
lets were then fixed in 4% paraformaldehyde and permeabilized
with 10% saponin in PBS with 0.1% BSA prior to in situ CuAAC re-
action. Fluorescent azide reporters were reacted with dendrimer
conjugates for 30 min with Tris (100 mm, pH 8.5), CuSO4 (1 mm),
fluorescent azide reporters (1–100 mm), and ascorbic acid (100 mm).
The staining solution was prepared fresh for each experiment.
After staining, the cells were washed twice with 10% saponin/BSA
solution and resuspended in PBS/BSA prior to flow cytometry anal-
ysis.
Confocal laser scanning microscopy
KB cells were seeded as described above on glass-bottomed Petri
dishes. After the cells were adhered, they were treated with dendri-
mer conjugates and incubated at 37 8C under 5% CO2 for 1 h.
After incubation, the cells were washed three times with PBS, then
fixed with 4% formaldehyde at room temperature for 15 min. After
fixation, the cells were washed and permeabilized with 0.25%
Triton-X100 for 20 min. The in situ CuAAC reaction was performed
on the monolayer of cells by using the same CuAAC protocol as
that described above. The cells were then washed twice with 0.1%
BSA/PBS solution and stained with DAPI and ProLong Gold Anti-
fade Reagent (Life Technologies, Carlsbad, CA, USA). Confocal
images were obtained on an Olympus FV-500 confocal microscope
with a 1003, 1.4 NA oil-immersion objective. To visualize AF488, the
488 nm line of an argon-ion laser was used for excitation, and the
emission was filtered at 505–525 nm. To visualize AF555, the
543 nm line of a He–Ne laser was used for excitation, and the emis-
sion was filtered at 555–625 nm.
RNA isolation, reverse transcription, and real-time poly-
merase chain reaction
After washing the cells, total RNA was isolated and extracted with
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA (500 ng)
was amplified by using the Message Amp II RNA Kit (Ambion,
Austin, TX, USA) and analyzed in triplicate by RT-PCR. Expression
was normalized to glyceraldehyde 3-phosphate dehydrogenase
and represented as the fold-change over control. Primers were pur-
chased from Life Technologies (Carlsbad, CA, USA).
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